Everolimus for treatment-refractory seizures in TSC: Extension of a randomized controlled trial

BACKGROUND: EXamining everolimus In a Study of Tuberous sclerosis 3 (EXIST-3) demonstrated significantly reduced seizure frequency (SF) with everolimus vs placebo. In this study, we evaluate the long-term efficacy and safety of everolimus for tuberous sclerosis complex (TSC)-associated treatment-ref...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Neurol Clin Pract
Autori principali: Franz, David N., Lawson, John A., Yapici, Zuhal, Ikeda, Hiroko, Polster, Tilman, Nabbout, Rima, Curatolo, Paolo, de Vries, Petrus J., Dlugos, Dennis J., Voi, Maurizio, Fan, Jenna, Vaury, Alexandra, Pelov, Diana, French, Jacqueline A.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Lippincott Williams & Wilkins 2018
Soggetti:
Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6276348/
https://ncbi.nlm.nih.gov/pubmed/30564495
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/CPJ.0000000000000514
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi